Brain, Behavior, and Immunity
| Autor: | Almeida, Amanda Cristina Galvão Oliveira de, Quarantini, Lucas de Castro, Sampaio, Aline Santos, Lyra, André Castro, Parise, Carmen Lívia, Paraná, Raymundo, Oliveira, Irismar Reis de, Koenen, Karestan C., Scippa, Ângela Marisa de Aquino Miranda, Guindalini, Camila |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Repositório Institucional da UFBA Universidade Federal da Bahia (UFBA) instacron:UFBA |
| DOI: | 10.1016/j.bbi.2011.06.001 |
| Popis: | texto completo: acesso restrito. p. 1491–1497. Submitted by Ana Valéria de Jesus Moura (anavaleria_131@hotmail.com) on 2012-02-25T15:04:11Z No. of bitstreams: 1 nps67.tmp.pdf: 109375 bytes, checksum: cba60c9ff3e1bf105dcfa759ed73a0f7 (MD5) Made available in DSpace on 2012-02-25T15:04:11Z (GMT). No. of bitstreams: 1 nps67.tmp.pdf: 109375 bytes, checksum: cba60c9ff3e1bf105dcfa759ed73a0f7 (MD5) Previous issue date: 2011 Background: Major depression is a frequent adverse effect of interferon-alpha (IFN-a) therapy. Although the indoleamine 2,3-dioxygenase (IDO) enzyme seems to be involved in the pathophysiology of IFN-a-induced depression, no pharmacogenetic study has investigated whether variation in the IDO gene mod-ifies vulnerability to this adverse effect. Methods: A cross-sectional study assessing 277 hepatitis C patients recruited in two specialized outpa-tient clinics of Brazil. They were interviewed with the Mini International Neuropsychiatric Interview (MINI) approximately 1 month after the end of IFN-a plus ribavirin therapy. Genomic DNA of individuals was extracted from venous blood. Three IDO single-nucleotide polymorphisms (SNPs) were genotyped (rs3824259; rs10089084 and rs35099072).Results: MINI indicated that 21.3% of the sample met criteria for a major depressive episode during the course of IFN-a therapy. No association with the diagnosis of a major depressive episode during the course of IFN-a therapy was observed genotype or allele-wise (p > 0.05). Current major depression and/or current anxiety disorder was significantly associated with IFN-a-related depression (p < 0.005). However, gender, age, route of infection, result of the antiviral treatment, past history of substance use disorders, depression or any other psychiatric disorder showed no association with IFN-a-related depression (p > 0.05). Conclusions: Our results suggest no influence of the variants in the IDO gene and the diagnosis of inter- feron-a-related depression in the Brazilian population. Interferon-a-related depression may impose per-sistent psychopathology on at least 15% of the depressed patients even 2 years after antiviral therapy termination. The cross-sectional design is a limitation of our study, predisposing memory bias. Prospec- tive pharmacogenetic studies are warranted to continue investigation of the impact of IDO polymorphisms on the development of IFN-a-induced depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|